54.73 USD
+0.45
0.83%
Updated Aug 26, 1:17 PM EDT
1 day
0.83%
5 days
0.51%
1 month
9.42%
3 months
-5.28%
6 months
-10.89%
Year to date
-18.74%
1 year
-24.36%
5 years
-35.70%
10 years
3.05%
 

About: Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.

Employees: 3,900

0
Funds holding %
of 7,431 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,606% more call options, than puts

Call options by funds: $3.91M | Put options by funds: $229K

1% less repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 95

4% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 45

2.39% less ownership

Funds ownership: 115.16% [Q1] → 112.76% (-2.39%) [Q2]

3% less funds holding

Funds holding: 278 [Q1] → 270 (-8) [Q2]

15% less capital invested

Capital invested by funds: $2.15B [Q1] → $1.82B (-$331M) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$61
11%
upside
Avg. target
$65
18%
upside
High target
$68
24%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Piper Sandler
Matt O'Brien
24%upside
$68
Overweight
Maintained
31 Jul 2025
Needham
Mike Matson
11%upside
$61
Hold
Downgraded
12 Jun 2025

Financial journalist opinion

Based on 11 articles about CNMD published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Why Conmed (CNMD) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Conmed (CNMD) is a Top Value Stock for the Long-Term
Positive
Zacks Investment Research
4 days ago
Here's Why Conmed (CNMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Conmed (CNMD) is a Strong Growth Stock
Positive
Zacks Investment Research
2 weeks ago
Why Conmed (CNMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Conmed (CNMD) is a Top Momentum Stock for the Long-Term
Neutral
Business Wire
2 weeks ago
CONMED Corporation Announces Quarterly Cash Dividend
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, inc.
CONMED Corporation Announces Quarterly Cash Dividend
Positive
Zacks Investment Research
3 weeks ago
Why Conmed (CNMD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Conmed (CNMD) is a Top Growth Stock for the Long-Term
Positive
The Motley Fool
3 weeks ago
Conmed (CNMD) Q2 EPS Jumps 17%
Conmed (CNMD) Q2 EPS Jumps 17%
Conmed (CNMD) Q2 EPS Jumps 17%
Positive
Zacks Investment Research
3 weeks ago
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
CNMD reports solid second-quarter results, driven by improving sales across both segments.
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
Neutral
Seeking Alpha
3 weeks ago
CONMED Corporation (CNMD) Q2 2025 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Patrick J. Beyer - President, CEO & Director Todd W.
CONMED Corporation (CNMD) Q2 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
3 weeks ago
Compared to Estimates, Conmed (CNMD) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, Conmed (CNMD) Q2 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
3 weeks ago
Conmed (CNMD) Q2 Earnings and Revenues Top Estimates
Conmed (CNMD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $0.98 per share a year ago.
Conmed (CNMD) Q2 Earnings and Revenues Top Estimates
Charts implemented using Lightweight Charts™